TNBC is regarded as a more immunogenic breast cancer, highlighted by increased levels of genomic instability, raised expression of PD-L1 and greater responsiveness to immune checkpoint inhibitors (Barchiesi et al., 2021). Here, CD274 is linked to breast cancer.